GB0704394D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0704394D0
GB0704394D0 GBGB0704394.6A GB0704394A GB0704394D0 GB 0704394 D0 GB0704394 D0 GB 0704394D0 GB 0704394 A GB0704394 A GB 0704394A GB 0704394 D0 GB0704394 D0 GB 0704394D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0704394.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Senexis Ltd
Original Assignee
Senexis Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senexis Ltd filed Critical Senexis Ltd
Priority to GBGB0704394.6A priority Critical patent/GB0704394D0/en
Publication of GB0704394D0 publication Critical patent/GB0704394D0/en
Priority to PCT/GB2008/000761 priority patent/WO2008107677A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
GBGB0704394.6A 2007-03-07 2007-03-07 Compounds Ceased GB0704394D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0704394.6A GB0704394D0 (en) 2007-03-07 2007-03-07 Compounds
PCT/GB2008/000761 WO2008107677A2 (en) 2007-03-07 2008-03-06 Thiadiazole and oxadiazole derivatives for the treatment of neurodegenerative disorders

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0704394.6A GB0704394D0 (en) 2007-03-07 2007-03-07 Compounds

Publications (1)

Publication Number Publication Date
GB0704394D0 true GB0704394D0 (en) 2007-04-11

Family

ID=37966087

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0704394.6A Ceased GB0704394D0 (en) 2007-03-07 2007-03-07 Compounds

Country Status (2)

Country Link
GB (1) GB0704394D0 (en)
WO (1) WO2008107677A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
CN102898519B (en) 2005-11-30 2015-10-28 Abbvie公司 Monoclonal antibody of anti-amyloid beta protein and uses thereof
EP2289909B1 (en) 2005-11-30 2014-10-29 AbbVie Inc. Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
EP2177521A1 (en) * 2008-10-14 2010-04-21 Almirall, S.A. New 2-Amidothiadiazole Derivatives
EP2305660A1 (en) * 2009-09-25 2011-04-06 Almirall, S.A. New thiadiazole derivatives
EP2343287A1 (en) * 2009-12-10 2011-07-13 Almirall, S.A. New 2-aminothiadiazole derivatives
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
CA2804225C (en) * 2010-07-02 2018-05-01 Aska Pharmaceutical Co., Ltd. Heterocyclic compound and p27kip1 degradation inhibitor
CA2808187A1 (en) 2010-08-14 2012-02-23 Abbvie Inc. Amyloid-beta binding proteins
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
EP3027600B1 (en) 2013-07-31 2022-04-06 Novartis AG 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions
EP3275440B1 (en) * 2015-03-25 2022-05-04 National Center for Geriatrics and Gerontology Novel oxadiazole derivative and pharmaceutical containing same
CN105384736B (en) * 2015-10-28 2018-11-02 南昌大学 A kind of type Ⅳ collagen enzyme inhibitor and synthetic method
CN108794427B (en) * 2018-07-13 2022-07-29 江苏快达农化股份有限公司 Synthetic method of 1,3, 4-thiadiazole derivative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06001845A (en) * 2003-08-21 2006-05-04 Pfizer Prod Inc Compounds for the treatment of neurodegenerative disorders.
WO2005072731A1 (en) * 2004-01-29 2005-08-11 X-Ceptor Therapeutics, Inc. 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders
US7232820B2 (en) * 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
GB0608386D0 (en) * 2006-04-27 2006-06-07 Senexis Ltd Compounds

Also Published As

Publication number Publication date
WO2008107677A3 (en) 2008-10-30
WO2008107677A2 (en) 2008-09-12

Similar Documents

Publication Publication Date Title
GB0706793D0 (en) Compounds
GB0704407D0 (en) Compounds
GB0704394D0 (en) Compounds
GB0705672D0 (en) Compounds
GB0706173D0 (en) Compounds
GB0707092D0 (en) Compounds
GB0706165D0 (en) Compounds
GB0706168D0 (en) Compounds
GB0706188D0 (en) Compounds
GB0707034D0 (en) Compounds
GB0706174D0 (en) Compounds
GB0706167D0 (en) Compounds
GB0706187D0 (en) Compounds
GB0706189D0 (en) Compounds
GB0706190D0 (en) Compounds
GB0706164D0 (en) Compounds
GB0706170D0 (en) Compounds
GB0704939D0 (en) Compounds
GB0703756D0 (en) Compounds
GB0701985D0 (en) Compounds
GB0706790D0 (en) Compounds
GB0701969D0 (en) Compounds
GB0707489D0 (en) Compounds
GB0702891D0 (en) Compounds
GB0701197D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)